← All trials
NCT06518603
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2024
- Primary completion
- Nov 30, 2025
- Completion date
- Nov 30, 2026
- First posted
- Jul 24, 2024
- Last posted
- Oct 9, 2024
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- University Teaching Hospital, Lusaka, ZambiaCollaborator
- University of Alabama, BirminghamSponsor investigator
- Centre for Infectious Disease Research in Zambia (CIDRZ)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.